Exenatide (Byetta)

Exenatide, sold under the brand name Byetta, is a twice-daily injection that helps control blood sugar and supports weight loss. It was the first medication in the GLP-1 receptor agonist class — the same family as more recent drugs like semaglutide. It works by helping your body release insulin after meals, slowing stomach emptying, and reducing appetite.

Exenatide is a synthetic form of exendin-4, a 39-amino-acid peptide originally isolated from the saliva of the Gila monster lizard, and acts as a GLP-1 receptor agonist with 53% sequence homology to human GLP-1. It binds to GLP-1 receptors on pancreatic beta cells to enhance glucose-dependent insulin secretion, suppresses inappropriate glucagon release, slows gastric emptying, and activates anorexigenic pathways in the hypothalamus. The twice-daily formulation was the first GLP-1 receptor agonist approved by the FDA (2005) for type 2 diabetes, with weight loss as a demonstrated secondary benefit.

As the pioneering GLP-1 receptor agonist, exenatide paved the way for the modern era of highly effective medical weight management. Dr Joseph Wang at Accord Medical draws on experience across the full GLP-1 class to help patients understand which option best fits their health needs and lifestyle.